• • The G4·Sr2+-Ta/Cr fibrils incorporate tavaborole and crisaborole via boronic ester bonds and Sr2+ via G-quartet cation recognition, achieving dual structural reinforcement and bioactivity, unlike conventional G4·K+ fibrils.
• • The optimized gelation process enables fabrication of microneedle patches with pseudomembrane-penetrating capability, addressing the bottleneck of transmucosal permeation in topical OM therapies.
• • ROS-triggered drug release is achieved via boronic ester hydrolysis, ensuring on-demand therapeutic delivery specifically in the inflammatory microenvironment.
• • In vivo mouse experiments confirm treatment efficacy in controlling OM-associated inflammation, modulating oral microbiota homeostasis, and promoting angiogenesis at ulcer sites, validating the multifunctional platform.